Harmony Biosciences (HRMY) shareholders elect directors, ratify auditor and back pay
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. held its 2026 Annual Meeting of Stockholders, with 50,381,309 common shares represented in person or by proxy, constituting a quorum. Stockholders voted on the election of four Class III directors, ratification of the auditor, and an advisory say‑on‑pay proposal.
All four Class III director nominees were elected, including Geno Germano with 44,963,163 votes for and 1,524,142 withheld, and Troy Ignelzi with 32,813,495 votes for and 13,673,810 withheld. Deloitte & Touche LLP was ratified as independent registered public accounting firm with 49,385,510 votes for and 830,697 against.
Stockholders also approved, on a non‑binding, advisory basis, the compensation of the company’s named executive officers, with 33,249,862 votes for, 13,042,898 against, 194,545 abstentions, and 3,894,004 broker non‑votes.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares represented at meeting: 50,381,309 shares
Votes for Geno Germano: 44,963,163 votes
Votes for auditor ratification: 49,385,510 votes
+4 more
7 metrics
Shares represented at meeting
50,381,309 shares
Common stock represented in person or by proxy; quorum for 2026 Annual Meeting
Votes for Geno Germano
44,963,163 votes
Election as Class III director; votes for
Votes for auditor ratification
49,385,510 votes
For ratification of Deloitte & Touche LLP for year ending December 31, 2026
Votes against auditor ratification
830,697 votes
Against ratification of Deloitte & Touche LLP
Say-on-pay votes for
33,249,862 votes
For non-binding advisory approval of named executive officer compensation
Say-on-pay votes against
13,042,898 votes
Against non-binding advisory approval of named executive officer compensation
Broker non-votes on proposals 1 & 3
3,894,004 votes
Broker non-votes reported for director elections and say-on-pay
Key Terms
Emerging growth company, broker non-votes, independent registered public accounting firm, non-binding, advisory basis, +1 more
5 terms
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
broker non-votes financial
"Broker Non-Votes Geno Germano | 44,963,163 | 1,524,142 | 3,894,004"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm regulatory
"the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding, advisory basis regulatory
"The approval on a non-binding, advisory basis, of the compensation"
named executive officers financial
"the compensation of the Company’s named executive officers pursuant to the SEC’s compensation disclosure rules"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
FAQ
What did Harmony Biosciences (HRMY) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing four Class III directors, ratifying Deloitte & Touche LLP as auditor for 2026, and approving executive compensation on an advisory basis. All three proposals received sufficient support to pass based on the reported vote totals.
Were all Harmony Biosciences (HRMY) director nominees elected in 2026?
Yes, all four Class III director nominees were elected. For example, Geno Germano received 44,963,163 votes for and 1,524,142 withheld, while other nominees, including Troy Ignelzi, Ron Philip, and Andreas Wicki, Ph.D., also obtained more votes for than withheld.
How did Harmony Biosciences (HRMY) stockholders vote on the 2026 auditor ratification?
Stockholders ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 49,385,510 votes for, 830,697 votes against, and 165,102 abstentions, indicating strong support for continuing with the same external auditor.
Did Harmony Biosciences (HRMY) stockholders approve executive compensation in 2026?
Yes, stockholders approved executive compensation on a non‑binding, advisory basis. The vote totaled 33,249,862 for, 13,042,898 against, 194,545 abstentions, and 3,894,004 broker non‑votes, signaling majority support for the company’s named executive officer pay program disclosed under SEC rules.